Dihexa

Dihexa is a small nootropic peptide derived from angiotensin IV — an endogenous neuropeptide fragment — developed at Washington State University. In preclinical research, it is approximately 10 million times more potent than BDNF at inducing new synapse formation (synaptogenesis) — a remarkable finding that has generated significant scientific and research community interest. Dihexa is studied primarily for cognitive enhancement, Alzheimer's disease models, and age-related cognitive decline. Due to its extraordinary potency, it is classified as an advanced compound requiring careful dosing discipline.

Dihexa acts as a potentiator of hepatocyte growth factor (HGF) signaling, dramatically increasing the activity of the HGF/MET receptor tyrosine kinase system in the brain. The HGF/MET pathway is a master regulator of synaptogenesis — the formation of new synaptic connections between neurons. By amplifying this pathway, dihexa dramatically promotes dendritic growth, new synapse formation, and the long-term potentiation underlying memory and learning. It does not directly bind BDNF receptors but produces effects that parallel and even exceed BDNF supplementation in synapse formation assays. In Alzheimer's mouse models, dihexa has reversed cognitive deficits equivalent to those seen in early-to-moderate stages of the disease. Its long effective half-life means effects accumulate over several days of repeated dosing, requiring conservative initial dosing.

Dihexa was developed at Washington State University by Joseph Harding and colleagues as a derivative of angiotensin IV. The landmark 2013 paper in Neuropsychopharmacology demonstrated that dihexa was 10 million times more potent than BDNF at inducing synaptogenesis in neuronal culture models. In Alzheimer's disease mouse models (aged rats with scopolamine-induced cognitive deficits), dihexa restored performance in Morris Water Maze tasks. The HGF/MET receptor tyrosine kinase mechanism was confirmed via pharmacological blockade experiments showing synaptogenic effects were abolished by MET inhibitors. No human clinical trials have been conducted as of 2024. Preclinical safety data shows low acute toxicity, but long-term safety in humans remains uncharacterized.

Cognitive Restoration Research: Dihexa 10 mg daily (oral) for 4 weeks, 4-week break, re-evaluate. Transdermal Protocol: 15 mg dissolved in DMSO-based transdermal gel, applied to inner forearm daily for 4 weeks. Not recommended for stacking with other strong serotonergic or dopaminergic compounds until individual response is established. Most commonly used standalone at conservative doses.

Dihexa's side effect profile is not fully characterized due to limited human clinical data. In animal research, cognitive improvements were the dominant documented effect with minimal toxicity at research doses. In the research community, reported effects at human doses include vivid, highly detailed dreams (consistent with heightened hippocampal activity), increased mental sharpness and mental fatigue (increased demand for cognitive fuel), and occasional mood elevation. Anxiety or racing thoughts have been reported at higher doses. The most significant theoretical concern is its powerful pro-growth signaling — HGF/MET pathway upregulation has oncogenic potential in the presence of pre-existing tumor cells, making dihexa contraindicated in any subject with a history of cancer or malignant disease.

Store lyophilized dihexa or powder at -20°C for long-term storage. Protect rigorously from moisture, light, and heat. When dissolved in DMSO for transdermal application, the solution should be stored at -20°C in amber glass and used within 30 days. The compound is relatively stable in its dry form. Note: DMSO is a powerful solvent and penetration enhancer — appropriate skin protection (gloves) is required during handling and application.